Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical company operating a synergistic dual-track business comprising AI-driven drug discovery and pharmaceutical commercialization. Its discovery activities are built around AlgoraeOS, its proprietary artificial intelligence (AI) drug-combination prediction platform, developed in collaboration with the UNSW AI Institute with support from CSIRO Data61, together with a therapeutic pipeline comprising AI-116 for dementia and AI-168 for cardiovascular disease. Its commercial activities are conducted through its wholly owned subsidiary, which sources, licenses, registers and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
48

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,740.48	70.78	-0.91%
DAX 40	25,111.26	260.49	-1.03%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,656.46	68.57	-0.64%
HKSE	23,093.37	158.69	0.69%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,663.43	0.00	0.00%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%